Understanding how immunity affects the spread of SARS-CoV-2 in communities
Immunological drivers of the transition from epidemicity to endemicity of SARS-CoV-2 in a high transmission LMIC setting
This study is looking at how people's immune systems, influenced by past infections and vaccines, help determine if COVID-19 will become a regular virus in communities, especially in urban slums in Brazil, to better protect everyone from future outbreaks.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11012853 on NIH RePORTER |
What this research studies
This research investigates how the immune responses of populations, shaped by previous infections and vaccinations, influence the transition of SARS-CoV-2 from an epidemic to an endemic virus. By studying a cohort in an urban slum community in Brazil, the research aims to gather data on antibody levels and the effectiveness of different immune responses in preventing infections. The focus is on both systemic and mucosal immunity, which are crucial for understanding how to protect communities from future outbreaks. The findings could inform public health policies and strategies in low and middle-income countries.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living in urban slum communities in Brazil who have experienced high rates of SARS-CoV-2 infection.
Not a fit: Patients living in regions with low transmission rates or those who have not been exposed to SARS-CoV-2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for managing SARS-CoV-2 and similar viruses, ultimately reducing infection rates and enhancing community health.
How similar studies have performed: Other research has shown success in understanding immune responses to SARS-CoV-2, but this specific focus on low and middle-income countries is relatively novel.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Ko, Albert Icksang — Yale University
- Study coordinator: Ko, Albert Icksang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.